诺华制药(NVS.US):VHB937未达到其主要终点和次要终点。根据2期ASTRALS研究结果,已停止VHB937用于

格隆汇
Sep 16
诺华制药(NVS.US):VHB937未达到其主要终点和次要终点。根据2期ASTRALS研究结果,已停止VHB937用于肌萎缩侧索硬化症(ALS)的开发。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10